Search
Filters
Clear All
  • 1
  • 5

Phase

  • 1
  • 2
  • 1
  • 2
  • 6
  • 1

Found 6 Adenocarcinoma trials

A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

A
Anita Turk, MD
18-100 years
All genders
Phase 2
Interventional
This phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 are human genes that produce tumor suppressor …
Learn More

Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable Unresectable or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region

R
Ryan Rhome, MD
18-100 years
All genders
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary cancers who have previously undergone treatment with chemotherapy, surgery, photodynamic therapy, conventionally fractionated radiation treatment, or any combination of these therapies.
Learn More

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

A
Anita Turk, MD
18-100 years
All genders
Phase 2
Interventional
This phase II trial investigates how well the addition of olaparib following completion ofurgery and chemotherapy works in treating patients with pancreatic cancer that has beenurgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2.b is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid …
Learn More

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

M
Melissa Bear, MD
12-30 years
All genders
Phase 1/2
Interventional
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits ofgavivint in treating patients with solid tumors that has come back (recurrent) or does notd to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells …
Learn More

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

L
Lisa Landrum, MD, PhD, MS
18-100 years
Female
Phase 3
Interventional
This phase III trial studies how well letrozole with or without paclitaxel and carboplatin works in treating patients with stage II-IV low-grade serous carcinoma of the ovary,ube, or peritoneum. Letrozole is an enzyme inhibitor that lowers the amount ofgen made by the body which in turn may stop the growth …
Learn More

Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

P
Patrick Loehrer, MD
18-100 years
All genders
The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.
Learn More